Dexamethasone, all trans retinoic acid and interferon alpha 2a in patients with refractory multiple myeloma

Cancer Biotherapy and Radiopharmaceuticals

Volumn 14, Issue 1, 1999, Pages 23-26

  Avilés, Agustin ^a,b   Rosas, Alejandro ^a   Huerta Guzmán, Judith ^a   Talavera, Alejandra ^a   Cleto, Sergio ^a  

^a HOSPITAL DE ONCOLOGÍA   (Mexico)

^b NONE   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; CYCLOPHOSPHAMIDE; DEXAMETHASONE; EPIRUBICIN; MELPHALAN; MITOXANTRONE; PREDNISONE; RETINOIC ACID; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; HUMAN; HYPERGLYCEMIA; INTRAVENOUS DRUG ADMINISTRATION; MALE; MULTIPLE MYELOMA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROGNOSIS; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME; TUMOR GROWTH;

EID: 0032895218     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.1999.14.23     Document Type: Article

References (16)

1. Barlogie B, Smith L, Alexanian R. Effective treatment of advanced multiple Myeloma refractory to alkylating agents. New Engl J Medicine 1989; 310:1353.
2. Kyle RA, Greipp PR, Gertz MA. Treatment of refractory multiple myeloma and considerations for future therapy. Seminars in Oncology 1986; 13:326.
3. Buzaid AC, Durie BGM. Management of refractory myeloma. A Review. Journal of Clinical Oncology 1988;6:889.
4. Gimsing P, Bjerrum JW, Brandt E, Ellegard J, Evensen SA, Hansen MM, Hedenus M, Hippe E, Keldsen N, Palua Y, Rodjer S, Talstad F, Westin J, Wisloff F. Refractory myelomatosis with mitoxantrone in combination with vincristine and prednisone (NOP-regimen). A phase II sudy. British Journal of Haematology 1991; 77:73.
5. San Miguel JF, Moro M, Blade J, Guerras L, Hernández J, Jimenes-Galindo R, Ortega F, Gonzalez M. Combination of interferon and dexamethasone in refractory multiple myeloma. Hematological Oncology 1990;8:185.
6. Dimopoulus MA, Weber DM, Hester J, DeLasalle K, Champlin R, Alexanian R. Intensive sequential therapy for VAD resistant multiple myeloma. Leukemia Lymphoma 1994;13:479.
7. Giles FJ. Refractory multiple myeloma. Recent advances in therapy. Hematological Pathology 1995;9:121.
8. Dimopoulus MA, Hester J, Huh X, Champlin R, Alexanian R. Intensive chemotherapy with blood progenitor transplantation for primary resistant multiple myeloma. British Journal of Haematology 1994;87:730.
9. Alexanian R, Dimopoulus MA, De Lasalle K, Barlogie B. Primary dexamethasone treatment of multiple myeloma. Blood 1992;80:887.
10. Alexanian R, Barlogie B, Tuckers S. VAD-based rigemens as primary treatment for multiple myeloma. American Journal of Hematology 1991;88:86.
11. Dimopoulus MA, Weber O, DeLasalle KB, Alexanian R. Combination chemotherapy with interferon-dexamethasone or newly diagnosed patients with multiple myeloma. Cancer 1993; 72:2589.
12. Alexanian R, Dimopoulus MA. Management of multiple myeloma. Seminars in Hematology 1995; 32:20.
13. Bonnen EM. The therapy of multiple myeloma with the interferons. Cancer Treatment Reviews 1988;15:35.
14. Alexanian R, Barlogie B, Gutterman J. Alpha interferon combination therapy of resistant myeloma. American Journal of Clinical Oncology 1991;14:188.
15. 3 derivative alone or in association with dexamethasone. Blood 1996;88:4059.
16. Palumbo A, Battaglio S, Napoli P, Bruno B, Omede P, Boccadoro M, Pileri A. Retinoic acid inhibits the growth of human myeloma cells in vitro. British Journal of Haematology 1995; 89:555.